Skip to main
GERN
GERN logo

Geron (GERN) Stock Forecast & Price Target

Geron (GERN) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Geron Corp's approval of Rytelo in the European Union is anticipated to enhance revenue streams starting in 2026, with additional approvals expected within the first half of 2025, which could further complement the drug's U.S. launch. The potential for Rytelo to address relapsed/refractory myelofibrosis is believed to potentially double its commercial opportunity, particularly given its benefits in reducing transfusion burdens for patients despite associated risks. The company is focused on expanding physician prescribing and patient uptake through targeted education efforts, positioning itself for robust sales growth in newly identified market segments.

Bears say

Geron Corp's recent financial performance indicates troubling trends, particularly the slowdown in revenue growth due to the underwhelming uptake of Rytelo among second-line patients, which is vital for the drug's market expansion. Management's acknowledgment of flat revenue trends and a shift in key trial results to the second half of 2026 suggests a lack of near-term catalysts that could support recovery and growth. Additionally, lowered expectations for Rytelo's peak sales and potential risks related to clinical efficacy, market competition, and regulatory hurdles further contribute to a cautious outlook on the company's financial viability.

Geron (GERN) has been analyzed by 18 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Geron and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Geron (GERN) Forecast

Analysts have given Geron (GERN) a Buy based on their latest research and market trends.

According to 18 analysts, Geron (GERN) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Geron (GERN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.